Alamar Biosciences (NASDAQ:ALMR) Price Target Raised to $35.00

Alamar Biosciences (NASDAQ:ALMR) had its price objective raised by equities researchers at JPMorgan Chase & Co. from $32.00 to $35.00 in a research report issued on Tuesday,Benzinga reports. The firm currently has an “overweight” rating on the stock. JPMorgan Chase & Co.‘s target price suggests a potential upside of 5.42% from the stock’s current price.

ALMR has been the subject of a number of other research reports. Wall Street Zen upgraded shares of Alamar Biosciences to a “hold” rating in a research note on Saturday, April 25th. Stifel Nicolaus set a $32.00 target price on Alamar Biosciences in a report on Tuesday. Bank of America initiated coverage on shares of Alamar Biosciences in a research report on Tuesday, May 12th. They set a “neutral” rating and a $27.00 price target on the stock. TD Cowen reissued a “buy” rating on shares of Alamar Biosciences in a research note on Wednesday, July 15th. Finally, Leerink Partners began coverage on Alamar Biosciences in a research note on Tuesday, May 12th. They set an “outperform” rating and a $35.00 target price for the company. Four investment analysts have rated the stock with a Buy rating and two have assigned a Hold rating to the company. According to data from MarketBeat.com, the stock has an average rating of “Moderate Buy” and an average target price of $31.80.

Alamar Biosciences Trading Up 18.6%

NASDAQ:ALMR traded up $5.21 during trading hours on Tuesday, reaching $33.20. 140,909 shares of the stock were exchanged, compared to its average volume of 295,728. The company’s 50 day simple moving average is $24.58. The stock has a market capitalization of $2.30 billion and a PE ratio of -19.08. Alamar Biosciences has a twelve month low of $18.84 and a twelve month high of $33.49.

Alamar Biosciences (NASDAQ:ALMR) last announced its quarterly earnings data on Tuesday, August 11th. The company reported ($0.22) earnings per share for the quarter, beating the consensus estimate of ($0.36) by $0.14. The company had revenue of $29.43 million during the quarter. Analysts forecast that Alamar Biosciences will post -1.42 EPS for the current year.

Alamar Biosciences News Roundup

Here are the key news stories impacting Alamar Biosciences this week:

• Positive Sentiment: Alamar reported second-quarter revenue of $29.43 million, while its adjusted loss of $0.22 per share was better than the analyst consensus loss of $0.36. The earnings beat suggests improving operating execution. Alamar Q2 earnings report
• Positive Sentiment: Management issued 2026 revenue guidance of $116 million to $120 million, above the roughly $113.1 million analyst estimate. The company also outlined plans to place more than 100 instruments and generate over $400,000 in annual pull-through revenue per instrument, indicating confidence in demand for its platform. Alamar 2026 revenue outlook
• Positive Sentiment: Second-quarter revenue reportedly increased 82% year over year, highlighting rapid commercial expansion. Management’s earnings-call commentary also emphasized accelerating instrument adoption and recurring consumables revenue. Alamar Q2 earnings call highlights
• Positive Sentiment: Alamar expanded its global partnership with the Alzheimer’s Disease Data Initiative and Gates Ventures. The collaboration could broaden the use of Alamar’s proteomics technology in Alzheimer’s research and improve the company’s visibility with pharmaceutical and research customers. Alamar global partnership
• Negative Sentiment: Despite the earnings beat and strong growth, Alamar remains unprofitable. The quarterly loss and the absence of a specific profitability target leave investors focused on how quickly revenue growth can translate into improving margins and cash flow.

About Alamar Biosciences

Our mission is to power precision proteomics to enable the earliest detection of disease. We are a commercial-stage proteomics company establishing a gold standard in protein detection and analysis. Our proprietary NULISA technology was purpose-built to address the limitations of existing proteomics tools by detecting protein biomarkers at extremely low concentrations in non-invasive biological fluids, such as blood, with ultra-high sensitivity, high specificity, flexible multiplexing, broad dynamic range and seamless automation.